Locally Ablative Therapy in Oligo-Progressive Genitourinary Tumors (LAYOVER)

What this Trial Is About

This research aims to assess the clinical benefit of continuing systemic therapy combined with locally ablative therapies for patients with oligo-progressive solid tumors, specifically genitourinary cancers such as prostate cancer, urothelial carcinoma, and renal cell carcinoma. The primary goal is to measure disease control at 3 months, defined as ongoing systemic therapy without changes or permanent discontinuation following local ablative treatment. This is a phase 2 pragmatic study conducted at a single site. Participants will receive locally ablative therapy, which may include stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation, in addition to their current systemic therapy. The specific ablative therapy will be selected by the treating radiation oncologist or interventional radiologist. Participants must be on systemic therapy and able to continue it with no more than a 30-day break to allow for ablative treatment. The study will follow participants for up to 5 years after the first day of ablative local therapy. During the study, participants will be monitored for disease control, adverse events related to ablative therapy, overall survival, and time to treatment failure for up to 1 to 2 years depending on the measure. Researchers will assess disease status at 3 months post-treatment and track any grade 3 or higher adverse events. Follow-up evaluations and clinical assessments will occur regularly to observe the effects and safety of combining systemic therapy with locally ablative treatments.

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)